Skip to main content
ImmuneCited

Andrographis pour Upper Respiratory Tract Infections

B

Multiple randomized controlled trials and Cochrane-reviewed meta-analyses support andrographis for reducing the severity and duration of upper respiratory symptoms. One of the most evidence-backed herbal supplements for acute respiratory infections.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dandrographis\u0026condition\u003Dupper\u002Drespiratory\u002Dinfections'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

En conclusion

Multiple randomized controlled trials and Cochrane-reviewed meta-analyses support andrographis for reducing the severity and duration of upper respiratory symptoms. One of the most evidence-backed herbal supplements for acute respiratory infections.

Key Study Findings

Randomized Controlled Trial n=331 1.0 weeks Double-blind
Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common …
Dose: 200 mg/day vs: placebo Outcome: URTI symptom severity Effet: None p = 0.034

Population: Participants with uncomplicated URTI

Review
A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead …
Dose: None vs: None Outcome: URTI symptom severity Effet: None None

Population: COVID-19/URTI patients

Review
Plant-Based Support of Respiratory Health during Viral Outbreaks.
Dose: None vs: None Outcome: None Effet: None None

Population: None

Other n=179
Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study.
Dose: 60 mg vs: placebo Outcome: None Effet: None p = 0.0053

Population: None

Meta-Analysis n=1000
Safety of Andrographis paniculata: A systematic review and meta-analysis.
Dose: 95% vs: control Outcome: None Effet: None None

Population: upper respiratory tract infection

Key Statistics

7

Études

800

Participants

Positive

B

Note

Referenced Papers

Journal of agricultural … 2022 9 citations
Pharmacoepidemiology and drug … 2021 32 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

acute:
400 mg 3x/day for up to 7 days
general:
200 mg standardized extract (30% andrographolides) 2x/day

Limite supérieure : No established UL; short-term use (<14 days)

Posologies étudiées dans la recherche

Posologie Durée Effet N
200 mg/day 1.0 weeks Positive 331
None -- Positive --
None -- Mixed --
60 mg -- Positive 179
95% -- Neutral 1000
6 μg/mL -- Positive --
None -- Mixed --
18 G 4.0 weeks Mixed --

Moment optimal de prise : At first sign of symptoms; with meals

Safety & Side Effects

Effets indésirables signalés

  • Gastrointestinal discomfort (nausea, diarrhea)
  • Headache
  • Fatigue
  • Allergic reactions (rare)
  • Potential anti-fertility effects (high doses in animal studies)

Interactions connues

  • Anticoagulant and antiplatelet drugs (may increase bleeding risk)
  • Antihypertensive medications (additive blood pressure lowering)
  • Immunosuppressant medications (may counteract immunosuppression)

Apport maximal tolérable : No established UL; short-term use (<14 days)

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does Andrographis help with Upper Respiratory Tract Infections?
Based on 7 studies with 800 participants, there is moderate evidence from clinical studies that Andrographis may support Upper Respiratory Tract Infections management. Our evidence grade is B (Good Evidence).
How much Andrographis should I take for Upper Respiratory Tract Infections?
Studies have used various dosages. A commonly studied range is 400 mg 3x/day for up to 7 days. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Andrographis?
Reported side effects may include Gastrointestinal discomfort (nausea, diarrhea), Headache, Fatigue, Allergic reactions (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Andrographis and Upper Respiratory Tract Infections?
We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 800 total participants. The overall direction of effect is positive.

Related Evidence

Autres ingrédients pour Upper Respiratory Tract Infections

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.